This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

STENTYS Revenues For The First 9 Months Of 2013 Up 32% Over Prior Year

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing ® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9-months through September 30, 2013.
  • Trends in quarterly and 9-month 2013 revenues*
  9 months Quarterly - 3 months
€ thousands

9 months 2013

9 months 2012

% change

Q3 2013
      Q3 2012      

% change
Revenues 2,406.6       1,823.2       +32.0% 768.0       673.6       +14.0%

* Data reviewed by statutory auditors

Revenues for the third quarter of 2013 totaled €768.0 thousand, up 14% compared to the third quarter of 2012. The substitution of paclitaxel by compounds of the “limus” family, deemed more efficient, on all coronary drug-eluting stents on the market may currently slow down the STENTYS paclitaxel-eluting stent’s entry into new accounts and has yielded a more moderate growth rate this quarter. The first clinical results from the STENTYS Sirolimus-eluting stent (“limus” family) will be presented on October 29, and its commercialization outside of the United States is expected after CE Mark approval by the end of 2014.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs